Oberland Capital Deal History & Licensing Activity
Oberland Capital is a life sciences. Over the past three years, Oberland Capital has been involved in 1 licensing and acquisition transaction, with a primary focus on Gene Therapy (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Mega Deals
Oberland Capital Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Oberland Capital in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| eye gene therapy programs | MeiraGTx | Gene Therapy | Unknown | collaboration | Jul 8, 2026 |
Oberland Capital Pipeline Focus
Therapeutic areas and modalities where Oberland Capital is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Oberland Capital's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Oberland Capital Licensing & Deal Activity
Oberland Capital is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Oberland Capital ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Oberland Capital include Mega Deals (2 deals and trials). In terms of modality, Oberland Capital has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Oberland Capital and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Oberland Capital's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.